| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
Laboratory of Molecular Carcinogenesis, National Cancer Institute, Bethesda, Maryland 20892 [S. S., H. L. W., K. H. K.], and Otsuka Pharmaceutical Corporation, Rockville, Maryland 20854 [M. M. S.]
The hereditary dysplastic nevus syndrome (DNS) is an autosomal dominant disorder in which affected individuals have increased numbers of dysplastic (premalignant) nevi and a >100-fold increased risk of developing cutaneous melanoma. Epstein-Barr virus-transformed lymphoblastoid cell lines from patients with hereditary DNS have been shown to be hypermutable to UV radiation (M. I. R. Perera et al., Cancer Res., 46: 10051009, 1986). To examine the mechanism involved in this UV hypermutability, we used a shuttle vector plasmid, pZ189, which carries a 160-base pair marker gene, supF, and can replicate in human cells. pZ189 was treated with UV radiation and transfected into DNS6BE, a lymphoblastoid cell line from a patient with hereditary DNS. Plasmid survival after UV was similar with the DNS6BE line and with a lymphoblastoid cell line from a normal donor. Plasmid mutation frequency was greater with the DNS line in accord with the DNS cellular hypermutability. Base sequence analysis was performed on 69 mutated plasmids recovered from the DNS line. There were significantly more plasmids with single base substitution mutations (P < 0.01) in comparison to UV-treated plasmids passed through normal fibroblasts. pZ189 hypermutability and an increased frequency of single base substitutions was previously found with a cell line from a melanoma-prone xeroderma pigmentosum patient. These differences may be related to the increased melanoma susceptibility in both DNS and xeroderma pigmentosum.
1 To whom requests for reprints should be addressed, at Laboratory of Molecular Carcinogenesis, Building 37, Room 3E24, Bethesda, MD 20892.
Received 3/20/89. Revised 6/19/89. Accepted 8/ 4/89.
This article has been cited by other articles:
![]() |
P. Sarkar-Agrawal, I. Vergilis, N. E. Sharpless, R. A. DePinho, and T. M. Runger Impaired Processing of DNA Photoproducts and Ultraviolet Hypermutability With Loss of p16INK4a or p19ARF J Natl Cancer Inst, December 1, 2004; 96(23): 1790 - 1793. [Abstract] [Full Text] [PDF] |
||||
![]() |
K. H. Kraemer NRAS Hypermutability in Familial Melanoma With CDKN2A Mutations--Cause and Effect? J Natl Cancer Inst, June 4, 2003; 95(11): 768 - 769. [Full Text] [PDF] |
||||
![]() |
M. Eskandarpour, J. Hashemi, L. Kanter, U. Ringborg, A. Platz, and J. Hansson Frequency of UV-Inducible NRAS Mutations in Melanomas of Patients With Germline CDKN2A Mutations J Natl Cancer Inst, June 4, 2003; 95(11): 790 - 798. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. T. Landi, A. Baccarelli, R. E. Tarone, A. Pesatori, M. A. Tucker, M. Hedayati, and L. Grossman DNA Repair, Dysplastic Nevi, and Sunlight Sensitivity in the Development of Cutaneous Malignant Melanoma J Natl Cancer Inst, January 16, 2002; 94(2): 94 - 101. [Abstract] [Full Text] [PDF] |
||||
![]() |
S. E. Tobi, D. D. Levy, M. M. Seidman1, and K. H. Kraemer1 Sequence-dependent mutations in a shuttle vector plasmid replicated in a mismatch repair deficient human cell line Carcinogenesis, July 1, 1999; 20(7): 1293 - 1301. [Abstract] [Full Text] [PDF] |
||||
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| Cancer Research | Clinical Cancer Research |
| Cancer Epidemiology Biomarkers & Prevention | Molecular Cancer Therapeutics |
| Molecular Cancer Research | Cancer Prevention Research |
| Cancer Prevention Journals Portal | Cancer Reviews Online |
| Annual Meeting Education Book | Meeting Abstracts Online |